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Abstract
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the pleura with a well-
established male predominance and causative link with asbestos exposure. We report four cases
of female patients with MPM referred for palliation of symptoms thought to be due to previous
non-pleural malignancy.
With emerging novel treatments for MPM, this article discusses four unusual cases of MPM
occurring in the setting of other malignancy, highlights the importance of considering a primary
diagnosis of MPM even in patients with other malignancy, and reinforces the benefits of video-
assisted surgical biopsy which allows simultaneous diagnosis and treatment.
Case reports
Four female patients were referred to our institution for
definitive treatment of pleural effusion (and one for per-
sistent pneumothorax). All had undergone CT imaging
and pleural fluid examination. In all cases the fluid was
diagnostic for malignancy but not for MPM. Assuming the
pleural effusions to be metastatic from their previous
malignancy, they were referred for surgical palliative man-
agement.
The first case was a 59-year-old woman with a history of
right-sided adenocarcinoma of the breast for which she
underwent mastectomy. After presenting 10 years later
with a right-sided pleural effusion and chest wall nodules,
she received anastrazole (aromatase inhibitor) and six
cycles of docetaxel (taxane) resulting in complete remis-
sion of the chest wall disease. The right-sided pleural effu-
sion persisted despite five separate episodes of drainage
and so she underwent right-sided video-assisted thoraco-
scopic surgical (VATS) cytoreductive pleurectomy. The
tumour was histologically confirmed to be MPM of the
epithelioid type (see Figure 1 and 2). A previous history of
asbestos exposure was not confirmed.
The second case involved a 78-year-old woman with a his-
tory of right-sided adenocarcinoma of the breast treated
with mastectomy and post-operative radiotherapy. She
presented 38 years later with a persistent right-sided pleu-
ral effusion. Cytological examination of the pleural aspi-
rate showed adenocarcinoma cells consistent with
primary breast origin. She was referred for VATS cytore-
ductive pleurectomy and at operation was found to have
infiltration of the pleura with tumour, histologically con-
firmed to be MPM of the epithelioid type. A previous his-
tory of asbestos exposure was not confirmed.
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The third case was a 74-year-old woman with a history of
endometrial carcinoma for which she underwent a hyster-
ectomy. She presented 20 years later with a persistent
right-sided pleural effusion. She underwent VATS cytore-
ductive pleurectomy and was found to have extensive
infiltration of the pleura, the diaphragm and the pericar-
dium with tumour. Histological examination of the
tumour confirmed MPM. There was no history of signifi-
cant exposure to asbestos.
The final case was a 39-year-old woman referred for the
surgical treatment of a persistent right-sided pneumotho-
rax and a right sided-pleural effusion. She had a history of
nodular sclerosing Hodgkin's lymphoma involving the
right lung, treated with mantle radiotherapy 14 years ear-
lier. At operation a bulla was noted in the right lung and
the right pleura was found to have a thickened and fibrous
appearance, possibly attributable to the previous radio-
therapy. The patient underwent VATS bullectomy and
cytoreductive pleurectomy. Histological and immunohis-
tochemical examination confirmed the diagnosis of epi-
thelioid MPM. There was no evidence of lymphoma in the
lung. A previous history of asbestos exposure was not con-
firmed.
Discussion
Malignant pleural mesothelioma (MPM) is an aggressive
tumour derived from the lining of the pleural cavity. It fre-
quently presents with dyspnoea and chest pain, and
uncommonly with cough, fatigue and weight loss. Occa-
sionally the diagnosis is suspected following a routine
chest radiograph, with pleural thickening or a pleural effu-
sion [1,2].
The incidence of MPM is 10–30 per million per year in
unselected male populations, and approximately 2 per
Histology demonstrating epithelioid mesothelioma {x 100} Figure 1
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million per year in female subjects [3]. More than 80 per
cent of MPMs develop in individuals with higher than
background exposure to asbestos, with an incidence as
high as 366/100,000 person-years in heavily exposed
workers [4]. The latent interval between first exposure to
asbestos and death is very long, with a mean of 41 years
and a range of 15–67 years in one series [5]. The use of
'asbestos exposure' as predictor of mesothelioma is how-
ever unreliable as many patients are unaware of such
exposure or when it occurred. Other potential causative
factors of MPMs include the simian virus 40 (SV40), other
environmental carcinogens such as erionite, ionising radi-
ation and genetic factors [6]. The role of radiotherapy in
inducing malignancy is well described but as yet the link
with mesothelioma is unclear.
MPMs have infrequently been reported in patients who
had received radiotherapy (with or without chemother-
apy) for previous non-pleural malignancy. Examples
include the development of MPMs after radiation therapy
for breast cancer [7-9] , Hodgkin's lymphoma involving
the lung [10-14] and Wilm's tumour with pulmonary
metastasis [15]. MPM following chemotherapy alone for
breast cancer has also been reported [16]. Isolated cases of
concurrence of MPM with breast cancer [7-9] and Hodg-
kin's lymphoma [10-14] are described.
These cases highlight the importance of the systematic
consideration of a diagnosis of MPM in all patients with
the typical presentation of a pleural effusion, irrespective
of any history of a previous malignancy (patients 1–3)
and regardless of previous asbestos exposure. The incor-
rect assumption that a pleural effusion is caused by the
known non-pleural malignancy can be a source of signifi-
cant delay between presentation and referral. This delay
(between 2 and 8 months in the present series) is impor-
Histology demonstrating epithelioid mesothelioma showing positivity for the immunohistochemical marker, calretinin {x 200} Figure 2
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tant in view of the fact that survival after diagnosis of
MPMs may be significantly improved as treatment strate-
gies are developed (17,18,19).
Cytological examination of the pleural aspirate in the
present series was non-diagnostic. This finding is consist-
ent with the previous reports that routine cytological
examination of pleural fluid is generally unreliable for the
diagnosis of MPMs, with a sensitivity of only 32% [20].
Similarly, 'blind' percutaneous needle biopsy specimens
give a diagnosis in less than 50% of cases [21]. The British
Thoracic Society correspondingly recommend that a neg-
ative pleural cytology or percutaneous pleural biopsy does
not exclude the diagnosis of MPM, and that ultrasound
and CT-guided biopsy, and thoracoscopic and surgical
biopsy techniques should be used to increase the likeli-
hood of accurate diagnosis [17].
The use of VATS techniques in the management of malig-
nant pleural effusions including MPM is well established
[19]. It now has few complications and allows both diag-
nosis and therapeutic intervention to be achieved at one
operative episode.
Three out of four cases in this series received significant
doses of radiotherapy as part of the original treatment of
their tumours. Previous cases have demonstrated the link
between radiotherapy and the development of malig-
nancy with a time frame not dissimilar to that for mes-
othelioma after asbestos exposure. This and other reports
now suggest that the combined exposure to both asbestos
and radiotherapy may be synergistic.
Conclusion
The diagnosis of malignant pleural mesotheliomas
should be actively considered in all patients presenting
with effusion relating to previous malignancies regardless
of asbestos history. As treatment options develop for mes-
othelioma early and accurate diagnosis is increasingly
important and best achieved by guided CT or VATS biopsy
since cytology and blind needle aspiration are of low yield
and may be misleading in this context. The exposure of
asbestos particles to a radiotherapy field carries a theoret-
ical risk of synergy, which requires further study [6].
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